The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://aishaqqqg306456.blgwiki.com/2000511/glp_3_retatrutide_a_comparative_analysis